SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D 2 (PGD 2 ) and thromboxane A 2 . Furthermore, PGD 2 concentrations in the airways increase with aging. PGD 2 action mediated via DP 2 receptors suppresses both innate and adaptive immune responses, by inhibiting interferon-λ and stimulation of myeloid monocyte-derived suppressor cells respectively. PGD 2 and thromboxane A 2 actions via the TP receptors activate platelets leading to a prothrombotic state. Ramatroban, a small-molecule antagonist of DP 2 and TP receptors, reverses viremia-associated proinflammatory, immunosuppressive5 and prothrombotic processes which are similar to those induced by SARS-Cov-2. Ramatroban, used for the treatment of allergic rhinitis in Japan for the past 20 years has an excellent safety profile. Therefore, Ramatroban merits investigation as a novel immunotherapy for the treatment of COVID-19 disease.
【저자키워드】 COVID-19, SARS-CoV-2 virus, immune function, Ramatroban, 【초록키워드】 Treatment, Immunotherapy, virus, airway, COVID-19 disease, proinflammatory, Platelet, Japan, receptors, receptor, respiratory, safety profile, Concentration, adaptive immune responses, allergic rhinitis, prostaglandin, multiorgan failure, prothrombotic state, Host, Cell, prothrombotic, virus, generate, suppresse, activate, inhibiting, stimulate, PGD, proliferate, 【제목키워드】 novel,